Thakare R, Dasgupta A, Chopra S
Division of Microbiology, CSIR-Central Drug Research Institute, Lucknow, Uttar Pradesh, India.
Drugs Today (Barc). 2018 Apr;54(4):245-254. doi: 10.1358/dot.2018.54.4.2800623.
Eravacycline is a novel, broad-spectrum, synthetic fluorocycline antibiotic for the treatment of complicated urinary tract infection (cUTI) and complicated intra-abdominal infection (cIAI) due to multidrug-resistant Gram-positive, Gram-negative and anaerobic bacteria that has demonstrated superior potency to that of currently marketed antibiotics. Tetraphase Pharmaceuticals has submitted a new drug application for eravacycline for the treatment of cIAI due to drug-resistant bacteria. In 2013, the U.S. Food and Drug Administration (FDA) granted eravacycline qualified infectious disease product designation for the treatment of cUTI and cIAI.
依拉环素是一种新型、广谱、合成的氟环素类抗生素，用于治疗由多重耐药革兰氏阳性菌、革兰氏阴性菌和厌氧菌引起的复杂性尿路感染（cUTI）和复杂性腹腔内感染（cIAI），已证明其效力优于目前市面上的抗生素。Tetraphase制药公司已提交依拉环素用于治疗耐药菌引起的cIAI的新药申请。2013年，美国食品药品监督管理局（FDA）授予依拉环素合格传染病产品认定，用于治疗cUTI和cIAI。
